Dr. Lal Path Labs

2,880.00
+25.30
(0.89%)
Market Cap
24,127.35 Cr
EPS
58.48
PE Ratio
48.92
Dividend Yield
0.84 %
52 Week High
3,653.95
52 Week Low
2,293.55
PB Ratio
11.00
Debt to Equity
0.10
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from21 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+61.90 %
+61.90 %
Hold
Hold+14.29 %
+14.29 %
Sell
Sell+23.81 %
+23.81 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
2,880.00
#1 24,127.35
#5 48.92
#1 2,554.80
#7 11.28
#1 492
#2 81.24
53.16
1,002.00
10,289.25
72.14
681.39
20.11
152
3.56
65.15
1,866.00
9,666.23
66.39
1,331.20
4.59
142
-20.00
63.94
1,068.40
5,661.93
62.26
687.35
8.63
98
25.58
58.44
779.45
2,516.83
30.79
717.16
25.65
81
10.70
59.17
320.20
1,667.63
52.91
252.09
14.77
31
14.29
47.92
1,599.00
1,372.36
29.06
96.47
25.47
49
-9.09
53.43
280.05
890.85
#1 9.47
1,110.95
35.04
-197
-18.52
50.46
280.10
547.39
28.63
147.04
#1 248.07
18
#1 175.00
54.82
182.00
126.75
83.40
41.78
6.34
1
28.57
66.97
Forecast
Actual
Growth Rate
Revenue Growth
11.28 %
Net Income Growth
35.88 %
Cash Flow Change
6.27 %
ROE
16.08 %
ROCE
4.17 %
EBITDA Margin (Avg.)
4.50 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
475
625
764
916
1,091
1,374
1,661
2,347
2,386
2,456
2,717
Fixed Assets
150
166
190
208
209
413
447
1,369
1,305
1,228
1,168
Current Assets
282
424
511
623
814
893
1,145
875
973
1,127
1,364
Capital Work in Progress
1
4
18
10
3
11
10
15
5
6
4
Investments
38
64
105
145
185
164
59
66
150
114
327
Other Assets
286
391
452
554
694
786
1,145
898
926
1,109
1,218
Total Liabilities
475
625
764
916
1,091
1,374
1,661
2,347
2,386
2,456
2,717
Current Liabilities
112
91
74
116
138
227
274
500
470
464
402
Non Current Liabilities
20
24
28
8
1
93
111
310
216
107
108
Total Equity
343
510
662
792
951
1,054
1,276
1,537
1,700
1,885
2,207
Reserve & Surplus
260
424
577
734
890
974
1,162
1,418
1,583
1,766
2,089
Share Capital
81
83
83
83
83
83
83
83
83
84
84

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
8
-5
2
37
64
67
48
134
-115
97
-68
Investing Activities
-114
-164
-137
-172
-100
-26
-212
-449
-287
-24
-303
Operating Activities
122
159
171
197
219
284
398
447
456
535
569
Financing Activities
-1
0
-32
13
-55
-190
-139
136
-283
-414
-334

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
55.23 %
55.23 %
55.23 %
55.23 %
55.23 %
55.05 %
55.05 %
55.05 %
55.03 %
55.01 %
54.61 %
54.60 %
54.60 %
54.60 %
53.92 %
53.91 %
53.91 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.00 %
1.83 %
0.00 %
0.00 %
0.00 %
26.15 %
25.42 %
26.82 %
26.82 %
23.91 %
DIIs
6.47 %
5.61 %
4.84 %
5.58 %
5.69 %
5.30 %
5.09 %
6.19 %
6.55 %
7.33 %
7.97 %
8.61 %
9.69 %
12.71 %
12.89 %
13.17 %
16.08 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
5.70 %
6.24 %
6.93 %
7.45 %
9.03 %
10.44 %
8.24 %
9.03 %
9.50 %
9.31 %
8.37 %
7.26 %
6.47 %
4.91 %
4.10 %
4.01 %
4.11 %
Others
32.60 %
32.92 %
32.99 %
31.74 %
30.05 %
29.22 %
31.63 %
27.73 %
27.09 %
28.35 %
29.05 %
29.53 %
3.09 %
2.35 %
2.27 %
2.10 %
2.00 %
No of Share Holders
68,845
94,123
1,25,953
1,35,068
1,71,846
1,84,508
1,71,602
1,79,636
1,80,163
1,74,444
1,60,679
1,49,901
1,46,741
1,31,189
1,16,606
1,16,236
1,15,699

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 4.5 6 12 20 12 6 24 24
Dividend Yield (%) 0.00 0.34 0.43 0.43 0.44 0.77 0.67 0.27 0.97 0.84

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jun 2025 2,906.55 2,771.25
06 Jun 2025 DIVIDEND Dividend
₹ 6.00 /share
06 Jun 2025 2,906.55 2,846.20
25 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Apr 2025 2,714.10 2,906.55
06 Feb 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
06 Feb 2025 2,801.45 2,801.45
05 Feb 2025 DIVIDEND Dividend
₹ 6.00 /share
05 Feb 2025 2,879.40 2,792.50
30 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Jan 2025 2,877.65 2,879.40
05 Nov 2024 DIVIDEND Dividend
₹ 6.00 /share
05 Nov 2024 3,252.50 3,070.90
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 3,329.85 3,252.50
20 Aug 2024 DIVIDEND Dividend
₹ 6.00 /share
20 Aug 2024 3,274.60 3,341.35
29 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Jun 2024 2,348.85 2,779.70
10 Jun 2024 DIVIDEND Dividend
₹ 6.00 /share
10 Jun 2024 2,348.85 2,783.80
13 Feb 2024 DIVIDEND Dividend
₹ 12.00 /share
13 Feb 2024 2,498.50 2,477.10
11 Aug 2023 DIVIDEND Dividend
₹ 6.00 /share
11 Aug 2023 2,354.65 2,298.00
11 Aug 2023 DIVIDEND Dividend
₹ 6.00 /share
11 Aug 2023 1,906.80 2,298.00
09 Aug 2022 DIVIDEND Dividend
₹ 6.00 /share
05 Aug 2022 2,144.50 2,415.45
23 Jun 2022 DIVIDEND Dividend
₹ 6.00 /share
22 Jun 2022 2,184.60 1,993.80
22 Aug 2021 DIVIDEND Dividend
₹ 6.00 /share
18 Aug 2021 3,556.35 3,852.65
22 Jul 2021 DIVIDEND Dividend
₹ 8.00 /share
20 Jul 2021 2,833.65 3,332.95
10 Feb 2021 DIVIDEND Dividend
₹ 6.00 /share
09 Feb 2021 2,247.35 2,391.40

Announcements

Shareholder Meeting / Postal Ballot-Scrutinizers Report9 days ago
Shareholder Meeting / Postal Ballot-Outcome of AGM10 days ago
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Letter Dispatched To The Members Of The Company- Weblink Of The Annual Report FY 2024-25Jun 04, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 04, 2025
31St Annual General Meeting To Be Held On June 28 2025Jun 04, 2025
Reg. 34 (1) Annual Report.Jun 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 30, 2025
Amended Trust DeedMay 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 25, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationApr 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 25, 2025
Annual General MeetingApr 25, 2025
Appointment Of Auditors Viz. Internal Auditor Cost Auditor And Secretarial AuditorApr 25, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 25, 2025
Record Date For Final Dividend For The Financial Year Ended March 31 2025Apr 25, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesApr 25, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated April 25 2025Apr 25, 2025
Financial Results For The Quarter And Financial Year Ended March 31 2025Apr 25, 2025
Announcement under Regulation 30 (LODR)-Credit RatingApr 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 21, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceApr 18, 2025
Board Meeting Intimation for Considering And Approving The Audited Financial Results Of The Company For The Quarter And FY Ended March 31 2025 And To Consider Recommending Final Dividend If AnyApr 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Grant Of Stock OptionsApr 09, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 31, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 20, 2025
Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited (A Wholly Owned Subsidiary Of The Company)Mar 18, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 14, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 10, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 07, 2025
Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited Wholly Owned SubsidiaryFeb 06, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Integrated Filing (Financial)Jan 30, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Amendment In Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationJan 30, 2025

Technical Indicators

RSI(14)
Neutral
53.78
ATR(14)
Less Volatile
69.73
STOCH(9,6)
Neutral
44.84
STOCH RSI(14)
Neutral
56.41
MACD(12,26)
Bearish
-2.63
ADX(14)
Weak Trend
18.74
UO(9)
Bearish
48.79
ROC(12)
Downtrend And Accelerating
-0.87
WillR(14)
Neutral
-40.56

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Flexi Cap Direct Plan-Growth
0.00%
-2100000
-0.77%
-0.78%
Nippon India Pharma Fund Direct-Growth
0.00%
-709112
-2.37%
-2.38%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-650000
-0.58%
-0.60%
Nippon India Small Cap Fund Direct- Growth
0.00%
-645485
-0.29%
-0.31%
HDFC ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-570000
-0.97%
-0.97%
Sundaram Mid Cap Fund Direct-Growth
0.00%
-515995
-1.16%
-1.22%
PGIM India Midcap Fund Direct-Growth
0.00%
-388808
-0.98%
-1.02%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-375619
-0.24%
-0.26%
SBI Dividend Yield Fund Direct - Growth
0.00%
-330000
-1.01%
-1.02%
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth
0.00%
-300000
-0.37%
0.00%
Tata Balanced Advantage Fund Direct - Growth
0.00%
-290812
-0.79%
-0.77%
Sundaram Large and Mid Cap Fund Direct-Growth
0.00%
-290000
-1.21%
-1.23%
SBI ESG Exclusionary Strategy Fund Direct Plan-Growth
0.00%
-250000
-1.22%
-1.25%
NJ Balanced Advantage Fund Direct - Growth
0.00%
-200197
-1.47%
-1.50%
HDFC Retirement Savings Fund Equity Plan Direct-Growth
0.00%
-200000
-0.86%
-0.53%
Canara Robeco Large and Mid Cap Fund Direct-Growth
0.00%
-195305
-0.22%
-0.22%
NJ Flexi Cap Fund Direct - Growth
0.00%
-168321
-2.08%
-2.12%
Tata Multicap Fund Direct - Growth
0.00%
-155000
-1.41%
-1.46%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
-153386
-0.88%
-0.56%
Baroda BNP Paribas Multi Cap Fund Direct-Growth
0.00%
-125800
-1.23%
-1.43%
Mirae Asset Small Cap Fund Direct-Growth
0.00%
-121775
-2.15%
-2.43%
Tata India Innovation Fund Direct-Growth
0.00%
-120000
-1.94%
-2.01%
SBI Retirement Benefit Fund - Aggressive Plan Direct - Growth
0.00%
-110000
-1.06%
-1.11%
Kotak Balanced Advantage Fund Direct - Growth
0.00%
-109670
-0.18%
-0.18%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-109196
-1.78%
-1.38%

About Dr. Lal Path Labs

Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.
Listing Date
23 Dec, 2015(9 Years, 15 days)
Chairperson NameArvind Lal